Processa Pharmaceuticals, Inc. Earnings Per Share (Basic)
Processa Pharmaceuticals, Inc. (PCSA) reported Earnings Per Share (Basic) of -$1.19 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-14
- Processa Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$1.19.
- Processa Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$1.29.
- Processa Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-12-31 was $0.05, a 85.36% decline year-over-year.
- Processa Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.07.
- Processa Pharmaceuticals, Inc. earnings per share, basic for fiscal 2025 was -$10.36.
- Processa Pharmaceuticals, Inc. earnings per share, basic for fiscal 2024 was -$96.78.
- Processa Pharmaceuticals, Inc. earnings per share, basic for fiscal 2023 was -$8.48.
- Processa Pharmaceuticals, Inc. earnings per share, basic for fiscal 2022 was -$34.05.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.19 10-Q · filed 2026-08-14 | -$2.47 10-Q · filed 2026-08-14 | $0.47 derived: net income ÷ weighted average shares · filed 2026-08-14 | $3.28 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||||
| 2026-03-31 | -$1.29 10-Q · filed 2026-05-07 | $0.20 derived: net income ÷ weighted average shares · filed 2026-05-07 | $1.60 derived: net income ÷ weighted average shares · filed 2026-05-07 | $3.05 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||||
| 2025-12-31 | $0.05 derived: net income ÷ weighted average shares · filed 2026-03-18 | $0.62 derived: net income ÷ weighted average shares · filed 2026-03-18 | $1.52 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$10.36 10-K · filed 2026-03-18 | ||||
| 2025-09-30 | -$0.07 10-Q · filed 2025-11-06 | -$0.31 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.41 10-Q · filed 2025-11-06 | -$1.28 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||||
| 2025-06-30 | -$6.26 10-Q · filed 2026-08-14 | -$0.25 10-Q · filed 2025-08-07 | -$13.48 10-Q · filed 2026-08-14 | -$0.55 10-Q · filed 2025-08-07 | $3.94 derived: net income ÷ weighted average shares · filed 2026-08-14 | $13.01 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||
| 2025-03-31 | -$7.58 10-Q · filed 2026-05-07 | -$0.30 10-Q · filed 2025-05-08 | $1.41 derived: net income ÷ weighted average shares · filed 2026-05-07 | $5.85 derived: net income ÷ weighted average shares · filed 2026-05-07 | $29.77 derived: net income ÷ weighted average shares · filed 2026-05-07 | |||
| 2024-12-31 | $0.33 derived: net income ÷ weighted average shares · filed 2026-03-18 | $2.46 derived: net income ÷ weighted average shares · filed 2026-03-18 | $13.82 derived: net income ÷ weighted average shares · filed 2026-03-18 | -$96.78 10-K · filed 2026-03-18 | -$3.87 10-K · filed 2025-03-20 | |||
| 2024-09-30 | -$1.03 10-Q · filed 2025-11-06 | -$2.04 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$3.13 10-Q · filed 2025-11-06 | -$4.55 derived: net income ÷ weighted average shares · filed 2025-11-06 | ||||
| 2024-06-30 | -$1.01 10-Q · filed 2025-08-07 | -$2.11 10-Q · filed 2025-08-07 | -$3.56 derived: net income ÷ weighted average shares · filed 2025-08-07 | -$4.98 derived: net income ÷ weighted average shares · filed 2025-08-07 | ||||
| 2024-03-31 | -$1.11 10-Q · filed 2025-05-08 | -$2.65 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$4.14 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$5.98 derived: net income ÷ weighted average shares · filed 2025-05-08 | ||||
| 2023-12-31 | -$1.71 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$3.25 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$5.19 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$8.48 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | -$1.54 10-Q · filed 2024-10-30 | -$0.08 10-Q · filed 2023-11-13 | -$3.48 derived: net income ÷ weighted average shares · filed 2024-10-30 | -$6.81 10-Q · filed 2024-10-30 | -$0.34 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | -$1.94 10-Q · filed 2024-08-13 | -$0.10 10-Q · filed 2023-08-10 | -$5.34 10-Q · filed 2024-08-13 | -$0.27 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | -$3.53 10-Q · filed 2024-05-10 | -$0.18 10-Q · filed 2023-05-15 | ||||||
| 2022-12-31 | -$34.05 10-K · filed 2024-03-29 | -$1.70 10-K · filed 2023-03-30 | ||||||
| 2022-09-30 | -$0.37 10-Q · filed 2023-11-13 | -$0.90 10-Q · filed 2023-11-13 | ||||||
| 2022-06-30 | -$0.32 10-Q · filed 2023-08-10 | -$0.53 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | -$0.20 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | -$0.75 10-K · filed 2023-03-30 | |||||||
| 2021-09-30 | -$0.19 10-Q · filed 2022-11-08 | -$0.54 10-Q · filed 2022-11-08 | ||||||
| 2021-06-30 | -$0.20 10-Q · filed 2022-08-11 | -$0.35 10-Q · filed 2022-08-11 | ||||||
| 2021-03-31 | -$0.14 10-Q · filed 2022-05-12 | |||||||
| 2017-12-31 | -$0.06 10-K · filed 2018-04-16 | |||||||
| 2016-12-31 | -$0.07 10-K · filed 2018-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |